Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gap up? sounds interessting dunno if shell get in...ahhhh
Maybe not red, but lower then where it opens.. Look at chart history on when it has big runs, no solid green candles next day after huge run, big gaps but usually close's lower then where it opens.
Looken back at chart history, prob gaps up in the AM and run in the AM but I would bet red by end of day.. IMO
not bad for a co in bk..
man wish I had been in on this
now its too risky to buy in imo
idk if itll go up tomoro, argh, why wasnt I in on this in the morning!!
0.29 printed huge Volume in just 2 hours. tomorrow to the moon?
Wow this was a friggen train ..i flipped it a few times, but left a lot of profit on the table here. Dident think it would be this strong on news not really not much meat for the company profit wise
if i would know what is going to be tomorrow i would buy in but idk. :)
I've been waiting, porfit's for me!! I got in at .11 early last week, and was wondering if it would move.
Bailed me out for the day from the losses on the other stocks. LOL.
Should this thing keep going?
wow missed another train to heaven. :/
PARABOLIC
.25 LOOKS LIKE A GOOD TIME TO TAKE PROFITS
deCODE Discovers a Major Risk Factor for Type 2 Diabetes
Dependent on Parent of Origin
A Single SNP That Confers Increased Risk if Inherited From the Father, but is Protective if Inherited From the Mother
REYKJAVIK, Iceland, December 16 /PRNewswire-FirstCall/ -- Scientists at deCODE genetics, Inc. (Nasdaq:DCGN) publish in the journal Nature the discovery of a version of a common single-letter variant in the sequence of the human genome (SNP) with a major impact on susceptibility to type 2 diabetes (T2D). The impact of the T2D variant is not only large, but unusual: if an individual inherits it from their father, the variant increases risk of T2D by more than 30% compared to those who inherit the non T2D-linked version; if inherited maternally, the variant lowers risk by more than 10% compared to the non T2D-linked version. Nearly one quarter of those studied have the highest risk combination of the versions of this SNP, putting them at a roughly 50% greater lifetime risk of T2D than the quarter with the protective combination. This is the second largest effect of any genetic variant for T2D apart from SNPs in TCF7L2, discovered by deCODE in 2006.
"We could make this discovery beacause we are in the unique position of being able to distinguish what is inherited from the mother from what is inherited from the father. This we can do because of the large amount of data we have assembled on the Icelandic population. These data empower us in many ways. For example, using our ability to impute sequence data, we can multiply by 100 times the amount of information generated by sequencing one individual. We can use these tools to discover and integrate rarer variants into our tests and scans, identify drug targets for licensing, and put our know-how at the disposal of our service customers. We believe that this is an important advantage for conducting large-scale whole sequence studies over the next couple of years," said Kari Stefansson, CEO of deCODE.
Because the risk is inherited and varies in this way, the SNP, located on chromsome 11, had never been linked to T2D even though it had been genotyped in large, traditional genome-wide association studies (GWAS). These do not distinguish between paternally and maternally inherited SNPs. But deCODE can track the parental origin of virtually any SNP in the genome of the tens of thousands of Icelandic participants in the company's gene discovery work. In this study, deCODE used its population-wide genealogy database and proprietary statistical tools to determine the parent of origin of a number of SNPs in some 40,000 Icelandic participants in the company's gene discovery programs. Some of these SNPs had previously been associated with different diseases and are located near "imprinted" genes - genes in which only the maternally or paternally inherited copy is "switched-on" to encode a protein. Five of these, one each in breast and skin cancer and three in T2D, showed that the parental origin of the variants affects the risk they confer.
The paper, "Parental origin of sequence variants associated with complex diseases," is published online at http://www.nature.com, and will appear in the December 17 print edition.
NICE BOUNCE HUH.....WOW .22'S NEXT...WEEEEEEEEEEE
DCGN weeeeeeeeeeee
too bad I own mine @ .155
congrats to all
DCGN file voluntary ch 11 on Nov 17 and down to 3¢.Now the delisting part I dont get b/c company is appealing the delisting on Nov 24. How in the heck can a company appeal a delisting when in ch 11? No Q yet (Amazing) Im watching to see how it all turn out as I never encounter anything like this. The company has filed such an appeal, which will stay the suspension and delisting through the conclusion of the appeals process. There is no guarantee that this appeal will be successful.
Im thinking of buying time so they can sell at a Higher price like they did @.164 but this should go down one would think to below 3¢.They will not win this appeal. It would be a first for me to see an ch 11 trading on Nasdaq Stock Market for whatever months.LOL!IMO
Tim sorry I can't send a private reply since I don't have a pay subs. but to answer your question I believe they can take up to 45 days to answer. However, you have to remember that part of the bk plan is to wipe out the commons which of course has to be approved by the bk courts. They had a hearing on the 9th and i have not found out what happened. The next meeting is for the creditors on the 21 or 22 of December I believe.
You can read more under the bankrupcty filing.
Don't forget they are trying to do all this to sell most of the assets to SAGA. So they won't have much left IMO
So I believe it will go lower before get higher on any good news
hey wes, whats goin on here buddy? didnt see any news to explain the move this week?
Just ran across this stock today. Will look to see what it does after lunch to make my move.
Looking to get in at .10.
Was this stock a p&d? Should I just pass on this? I seen the massive run up + volume, so if it is still mid game... just don't wanna jump in if it's time for the ship to sink.
Thoughts here?
read some of the previous posts.
They have been pretty detailed about what is going on....if you boufgt yesterday. you must be in the green. Take the 25% and run or let it ride.
Isnt this stock in BK?
Can someone give me a status update on this bad boy?
I got in yesterday, purely because it was running...then started reading up on it. (dumb, yes, but hey, made a small fortune :)
Is it heading to a Q or what?
Thanks in advance.
lol, have you covered your position?... expensive to short this one, isn't it?
aaaaahhhh!... me too... lol... great 2nd run... congrats all!
I believe that there were several institutions taking in the selling volume the last two weeks. Why? Its all a game and the retail trader never knows the strategy until its over.
Something is going on and the insiders know what is happening. The retail trader should take what he can and move on. Thats why I was happy with 175% yesterday. Anything at these levels is a gift. IMHO. Can the gap at .20 close? yes. can we bounce at the .25 50 DMA, yes....is it worth the risk for me? no.
Your question on volume. I believe it is the istitutions pumping it up on their qwuak box
why do you think is the volume?
WOW....congrats to those of you that held after yesterdays run......My bad for closing out early.
eod run?... weeeeeeeeeeeeeeee lol... great day for DCGN... I'm out for today... sold everything .010+... with little profit, a few hundret bucks... pocket money :) ... let's see what trading brings us tomorrow... GL all!
I assume this as received some of its additional power from Reg Sho list, shorts covering? Can anyone verify or have input on this possibility?
Yes it is public site and is for the sec record. Here is the company filings.
http://www.mffais.com/dcgn
Great info.......good find. is that a public site?please post.
It was all a set up. this may have legs to go higher. i will look for a pullback. 150% in one day, 175% since last week. I figure I would take the money.
LJPC was in this same shape a month back and today announced a buyout. just wondering if the same thing may be happening here.
I am wondering why the fundies opened new positions here the last couple of days???? ant thoughts on why????
http://www.mffais.com/dcgn
Filed As-Of/On Form Fullname Fund Class Shares Activity Shares Change Shares Pct. Change Hypothetical Old Value Hypothetical New Value Hypothetical Value Chg. Hypotheticals Return Hypotheticals Results Director Other Ten Pct Officer Officer Title News Article History
2009-12-07 2009-09-30 13F-HR/A Rbc Dain Rauscher Inc Institution 4,245 Added More 2,000 89.08 % $170 $170 $0 0.00 % $0 News Article History of Rbc Dain Rauscher Inc Ownership Of Decode Genetics Inc
2009-11-17 2009-09-30 13F-HR/A Credit Suisse First Boston Institution 50,100 Added More 100 0.20 % $2,004 $2,004 $0 0.00 % $0 News Article History of Credit Suisse First Boston Ownership Of Decode Genetics Inc
2009-11-17 2009-09-30 13F-HR Wells Fargo And Co Institution 4,525 Sold Some -2,000 -30.65 % $181 $181 $0 0.00 % $0 News Article History of Wells Fargo And Co Ownership Of Decode Genetics Inc
2009-11-16 2009-09-30 13F-HR Citadel L P Institution 22,443 Sold Some -6,417 -22.23 % $5,162 $898 $-4,264 -82.60 % $1,219 News Article History of Citadel L P Ownership Of Decode Genetics Inc
2009-11-16 2009-09-30 13F-HR Northern Trust Corp Institution 37,407 Added More 15,597 71.51 % $8,604 $1,496 $-7,107 -82.60 % $-2,963 News Article History of Northern Trust Corp Ownership Of Decode Genetics Inc
2009-11-16 2009-09-30 13F-HR Shaw D E And Co Inc Institution Sold All -11,397 -100 % -82.60 % $2,165 News Article History of Shaw D E And Co Inc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Ameriprise Financial Inc Institution 6,000 Added More 5,000 500.00 % $1,200 $240 $-960 -80.00 % $-800 News Article History of Ameriprise Financial Inc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Barclays Plc Institution 425 No Change 0 0 % $85 $17 $-68 -80.00 % $0 News Article History of Barclays Plc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Credit Agricole S A Institution 19,700 No Change 0 0 % $3,940 $788 $-3,152 -80.00 % $0 News Article History of Credit Agricole S A Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Knight Capital Group Inc Institution 25,002 Added More 3,333 15.38 % $5,000 $1,000 $-4,000 -80.00 % $-533 News Article History of Knight Capital Group Inc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Price T Rowe Associates Inc Institution 7,473,403 Sold Some -8,800 -0.11 % $1,494,681 $298,936 $-1,195,744 -80.00 % $1,408 News Article History of Price T Rowe Associates Inc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Renaissance Technologies Corp Institution 123,116 Added More 63,616 106.91 % $24,623 $4,925 $-19,699 -80.00 % $-10,179 News Article History of Renaissance Technologies Corp Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR/A United Capital Financial Advisersinc No Data 85,909 No Change 0 0 % $17,182 $3,436 $-13,745 -80.00 % $0 News Article History of United Capital Financial Advisersinc Ownership Of Decode Genetics Inc
2009-11-13 2009-09-30 13F-HR Vanguard Group Inc Institution 626,700 No Change 0 0 % $125,340 $25,068 $-100,272 -80.00 % $0 News Article History of Vanguard Group Inc Ownership Of Decode Genetics Inc
2009-11-12 2009-10-30 13F-HR Td Asset Management Inc Institution 88,800 Sold Some -5,000 -5.33 % $20,424 $3,552 $-16,872 -82.60 % $950 News Article History of Td Asset Management Inc Ownership Of Decode Genetics Inc
2009-11-12 2009-09-30 13F-HR Barclays Global Investors Uk Holdings Ltd Institution Sold All -154,357 -100 % -82.60 % $29,328 News Article History of Barclays Global Investors Uk Holdings Ltd Ownership Of Decode Genetics Inc
2009-11-12 2009-09-30 13F-HR Credit Suisse Institution 1,600 New Holding 1,600 100 % $368 $64 $-304 -82.60 % $-304
I closed my position. dont look a gift horse in the mouth. 175% not worth the risk. I dont trust the move.
Perhaps the volume is bacause of tomorrow's hearing?
Any thoughts??
Deep See. Why do u think is ths volume today?
nice day here.....enjoy the ride
on the other hand the bid support is strong... phps I will hold some of my shares... sold already 60% of them... seems to be a huge dead cat bounce... lol... :) GL all!
it has filed for bankruptcy in Nov.09, I'm not sure... loaded some < .09 on the volume alert... but will unload now at .105$, without any news... to hot for me... cheers
DCGN has closed above the upper band by 37.6%. Bollinger Bands are 73.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to DCGN's normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
time to buy? are you in at what price?
searched but didn't found anything... insiders? the volume of 2 hours is worth 1.1 M$ thats 1/6 of the market cap...
any particular news here?
you are rigt!! .10+$ here we go...
Followers
|
17
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
276
|
Created
|
05/18/05
|
Type
|
Free
|
Moderators |
http://www.decode.com/
http://finance.yahoo.com/q/h?s=DCGN
deCODE genetics, Inc. operates as a biopharmaceutical company in the United States and Iceland. It applies its discoveries in human genetics to the development of drugs for common diseases. The company involves in human genetics, and integrated drug discovery and development activities to offer products and services in various areas, including DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery, and clinical development. It develops DG031 for the prevention of heart attack that completed a series of Phase II clinical trials in Iceland; and DG041 for peripheral artery disease, a form of atherosclerosis that constricts blood flow to the legs and arms, which completed the Phase I clinical program, as well as conducts a Phase II trial on behalf of the developer of a compound for asthma. deCODE genetics has a strategic alliance with Illumina, Inc. for the development and commercialization of DNA-based diagnostic tests in various disease areas; a collaboration with F. Hoffmann-La Roche for the codevelopment of inhibitors of PDE4 for the prevention and treatment of vascular disease; and an alliance with Merck & Co, Inc. to develop treatments for obesity. The company was co-founded by Kari Stefansson and Jeffrey Gulcher in 1996 and is headquartered in Reykjavik, Iceland.
Gallery View 4: (Full Sto, MACD, Aroon8)
[/chart
>Privacy fears as DNA testing firm deCODE Genetics goes bustMark Henderson, Science Editor
1 Comment
Recommend? (10)
(The Wellcome Trust/Reuters)
DeCODE Genetics has identifed dozens of genetic variations that affect common diseases
A leading genetics company that has pioneered personal DNA testing in health assessments went bust yesterday, raising privacy concerns about the sensitive data it holds.
DNA profiles belonging to thousands of people who have paid up to £600 for internet genetic tests are to be transferred to a new organisation, after deCODE Genetics filed for chapter 11 bankruptcy in a US court.
The fate of the Icelandic company, which has never turned a profit despite making a string of discoveries about the genetic origins of common diseases, has fuelled fresh debate about access to DNA data.
The genetic records of its customers will now be held by Saga Investments, a venture capital group that has agreed to buy deCODE’s core science operations, including its deCODEme personalised genetic testing service.
Related Links
Scientists identify gene linked to empathy
Why we can talk, but chimps can’t answer
Biotechnology pioneer faces financial crisis
Kari Stefansson, deCODE’s chief executive, told The Times that ownership of genetic data remained with the company’s customers and that Saga would be bound by a privacy policy that prevents disclosure of data to third parties such as insurers, employers or doctors.
Industry experts said that Saga would want to maximise returns on its investment, and could still make wider use of data that some subscribers may find uncomfortable. Pooled and anonymised information, for example, could be sold to academic researchers or pharmaceutical companies.
Dan Vorhaus, a lawyer with the US firm Robinson, Bradshaw and Hinson, which specialises in genomics, said that while the new management would be bound by deCODE’s customer agreements, these were often unclear and contradictory.
“The ownership is going to change, and the people making decisions about how to run the company are going to change,” he said. “This information was held by deCODE, a scientific research organisation. What you have now is Saga, an investment company with a different agenda, very much focused on the bottom line.
“Within the range of allowable uses, deCODE’s new ownership may choose to use that information in a different way, and possibly to a greater extent, than was previously the case.”
Helen Wallace, of GeneWatch UK, a group that campaigns about the risks of genetic technologies, said the case showed that people who bought commercial DNA tests could not be confident that their data would not be put to other uses.
“This clearly introduces a layer of uncertainty beyond what people expected when they signed up. People do need to double check what they are signing up to. These companies often use broad consent, and I worry whether people know what their data might be used for in the long term," she added.
Dr Stefansson said: “We don’t own the genetic data of our customers, they own the data. We have no access to these data for anything except doing analysis for our customers. We are not selling genetic data, we will not do that.”
He likened the sale to that of a medical diagnostic company or a telecommunications business that holds sensitive data. “There is a change in ownership of a commercial enterprise with a commitment to its customers and keeping data according to certain ethical principles. That doesn’t really change.”
DeCODE Genetics was founded a decade ago as a commercial research business, and has identifed dozens of genetic variations that affect common diseases. Its £600 deCODEme service, which tests DNA for links to disease, was launched two years ago, though customer numbers have not been disclosed. The company has long been in financial trouble, and warned investors in April that it had insufficient funds to see out the year.
It filed a voluntary petition for chapter 11 bankruptcy in a Delaware court yesterday, which allows it to continue operating while its assets are auctioned. Saga was named as a “stalking horse” bidder that has agreed to buy its core operations, though other companies may still top its offer. Subscribers to deCODEme were sent an e-mail yesterday saying that the service would be unaffected by the bankruptcy and sale.
Dr Stefansson said: “This is the best outcome of a bad situation for us. The silver lining is that it allows us to continue. I sit here on a strange, cold rock in the North Atlantic with a strange mix of emotions.”
DeCODE’s bankruptcy comes just days after its main competitor selling personalised DNA tests, 23andMe, raised its prices, prompting suggestions that the fledgling industry is struggling to make consumer genetics pay.
Print
Email
Your Comments
1 Comment
(Displaying 1-1)
Order By:
Newest first Oldest first Most recommended
Report item as: (required) X Obscenity/vulgarity Hate speech Personal attack Advertising/Spam Copyright/Plagiarism Other Comment: (optional)
Edward Farmer wrote:
Dear Sir,
A quick but fundamental clarification to your piece on deCODE genetics' bankruptcy filing: the Iceland-based subsidiary that performs all of deCODE's human genetics work - manages its population resources, conducts its research and services, offers and processes its tests and genome scans,
and whose scientists and laboratories are licensed to undertake this work
- is not in bankruptcy. It continues all its operations without
interruption. This subsidiary (Islensk Erfdagreining, or IE) does so under
the same data and privacy protections as ever, rooted in the Icelandic
community and within a tried and tested regulatory environment.
The long and the short of it is that under the Chapter 11 process, IE,
currently owned by deCODE genetics, will likely be sold to another group of
investors as a going concern. Such a change in ownership of the operating
company will have no bearing on the terms under which the Icelandic
subsidiary manages and analyzes samples and data. Indeed, given the tone of
your story it seems important to emphasize that the Icelandic subsidiary
does not own these samples or data. They are owned by the individuals who
provide them and are only utilized for the specific purpose, whether
research or testing, agreed upon with those individuals and under the
regulatory protections under which we work. Thus these resources cannot be
sold and are not for sale, and IE's genetics operation cannot be put in a
box and taken somewhere else.
Yours sincerely,
Kari Stefansson
CEO, deCODE genetics
November 19, 2009 9:13 PM GMT on community.timesonline.co.uk Recommend? Report Abuse Permalink
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |